Vanessa L Kronzer1, Cynthia S Crowson2, Jeffrey A Sparks3, Elena Myasoedova4, John M Davis4. 1. Division of Rheumatology, Mayo Clinic, Rochester, MN. Electronic address: kronzer.vanessa@mayo.edu. 2. Division of Rheumatology, Mayo Clinic, Rochester, MN; Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 3. Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA. 4. Division of Rheumatology, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To determine the prevalence of comorbidities in rheumatoid arthritis (RA), discover which comorbidities might predispose to developing RA, and identify which comorbidities are more likely to develop after RA. PATIENTS AND METHODS: We performed a case-control study using a single-center biobank, identifying 821 cases of RA (143 incident RA) between January 1, 2009, and February 28, 2018, defined as 2 diagnosis codes plus a disease-modifying antirheumatic drug. We matched each case to 3 controls based on age and sex. Participants self-reported the presence and onset of 74 comorbidities. Logistic regression models adjusted for race, body mass index, education, smoking, and Charlson comorbidity index. RESULTS: After adjustment for confounders and multiple comparisons, 11 comorbidities were associated with RA, including epilepsy (odds ratio [OR], 2.13; P=.009), obstructive sleep apnea (OR, 1.49; P=.001), and pulmonary fibrosis (OR, 4.63; P<.001), but cancer was not. Inflammatory bowel disease (OR, 3.82; P<.001), type 1 diabetes (OR, 3.07; P=.01), and venous thromboembolism (VTE; OR, 1.80; P<.001) occurred more often before RA diagnosis compared with controls. In contrast, myocardial infarction (OR, 3.09; P<.001) and VTE (OR, 1.84; P<.001) occurred more often after RA diagnosis compared with controls. Analyses restricted to incident RA cases and their matched controls mirrored these results. CONCLUSION: Inflammatory bowel disease, type 1 diabetes, and VTE might predispose to RA development, whereas cardiovascular disease, VTE, and obstructive sleep apnea can result from RA. These findings have important implications for RA pathogenesis, early detection, and recommended screening.
OBJECTIVE: To determine the prevalence of comorbidities in rheumatoid arthritis (RA), discover which comorbidities might predispose to developing RA, and identify which comorbidities are more likely to develop after RA. PATIENTS AND METHODS: We performed a case-control study using a single-center biobank, identifying 821 cases of RA (143 incident RA) between January 1, 2009, and February 28, 2018, defined as 2 diagnosis codes plus a disease-modifying antirheumatic drug. We matched each case to 3 controls based on age and sex. Participants self-reported the presence and onset of 74 comorbidities. Logistic regression models adjusted for race, body mass index, education, smoking, and Charlson comorbidity index. RESULTS: After adjustment for confounders and multiple comparisons, 11 comorbidities were associated with RA, including epilepsy (odds ratio [OR], 2.13; P=.009), obstructive sleep apnea (OR, 1.49; P=.001), and pulmonary fibrosis (OR, 4.63; P<.001), but cancer was not. Inflammatory bowel disease (OR, 3.82; P<.001), type 1 diabetes (OR, 3.07; P=.01), and venous thromboembolism (VTE; OR, 1.80; P<.001) occurred more often before RA diagnosis compared with controls. In contrast, myocardial infarction (OR, 3.09; P<.001) and VTE (OR, 1.84; P<.001) occurred more often after RA diagnosis compared with controls. Analyses restricted to incident RA cases and their matched controls mirrored these results. CONCLUSION:Inflammatory bowel disease, type 1 diabetes, and VTE might predispose to RA development, whereas cardiovascular disease, VTE, and obstructive sleep apnea can result from RA. These findings have important implications for RA pathogenesis, early detection, and recommended screening.
Authors: Sam Norton; Gouri Koduri; Elena Nikiphorou; Josh Dixey; Peter Williams; Adam Young Journal: Rheumatology (Oxford) Date: 2012-10-19 Impact factor: 7.580
Authors: Nicolas Ellerby; Derek L Mattey; Jonathan Packham; Peter Dawes; Samantha L Hider Journal: Ann Rheum Dis Date: 2014-08-08 Impact factor: 19.103
Authors: Janet E Olson; Euijung Ryu; Kiley J Johnson; Barbara A Koenig; Karen J Maschke; Jody A Morrisette; Mark Liebow; Paul Y Takahashi; Zachary S Fredericksen; Ruchi G Sharma; Kari S Anderson; Matthew A Hathcock; Jason A Carnahan; Jyotishman Pathak; Noralane M Lindor; Timothy J Beebe; Stephen N Thibodeau; James R Cerhan Journal: Mayo Clin Proc Date: 2013-09 Impact factor: 7.616
Authors: Stephanie R Reading; Cynthia S Crowson; Richard J Rodeheffer; Patrick D Fitz-Gibbon; Hilal Maradit-Kremers; Sherine E Gabriel Journal: J Rheumatol Date: 2009-07-31 Impact factor: 4.666
Authors: Lorie L Geryk; Delesha M Carpenter; Susan J Blalock; Robert F DeVellis; Joanne M Jordan Journal: Clin Exp Rheumatol Date: 2015-03-24 Impact factor: 4.862
Authors: Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg Journal: Front Immunol Date: 2022-06-30 Impact factor: 8.786
Authors: Ella Nissan; Abdulla Watad; Arnon D Cohen; Kassem Sharif; Johnatan Nissan; Howard Amital; Ora Shovman; Nicola Luigi Bragazzi Journal: Int J Environ Res Public Health Date: 2021-04-10 Impact factor: 3.390
Authors: Tatiana D Saccon; Joseph M Dhahbi; Augusto Schneider; Yury O Nunez Lopez; Ahmad Qasem; Marcelo B Cavalcante; Lauren K Sing; Saleh A Naser; Michal M Masternak Journal: Biology (Basel) Date: 2022-03-25